Hybridoma Loss Prevention2021-10-08T22:43:38-04:00

Hybridoma Loss Insurance.

Hybridoma instability is common and costly.

Although scientists spend a significant amount of time and effort on continuously culturing hybridoma cell lines, poor growth or even cell death still occurs occasionally. Many factors, including long-term storage, repeated freeze-thaw cycles, improper handling, and contamination can all lead to failure of hybridoma survival causing permanent loss of important monoclonal antibodies (mAbs).

In addition, hybridoma cell lines are also known to undergo gene mutations and rearrangements over time, leading to antibody heterogeneity and batch-to-batch variability. In a recent study of 185 clonal hybridoma cell lines, nearly a third were found to contain additional heavy or light chain genes resulting in impaired affinity and specificity to the target antigen. In other cases, hybridomas may even lose the chromosome containing antibody genes, completely arresting the production of antibodies.

Rapid Novor has helped hundreds of researchers recover from the loss, death or mutation of their cell lines. Starting from just a small sample of antibody protein, we can return the amino acid sequence of the mAb with 100% accuracy. From there, a limitless supply of recombinantly expressed antibodies can be produced and the sequence stored indefinitely. Many antibody users choose to sequence their most valuable mAbs as an insurance policy in case they are discontinued. Some antibody users and producers choose to confirm the sequence of every batch of antibodies produced by hybridoma as part of their validation procedures.

Whitepaper: Prevalence of Secondary Light Chains

Services for hybridoma users.

By securing the protein sequencing, Rapid Novor’s next generation protein sequencing enables novel discoveries and project continuance. And by confirming the protein sequencing at different stages of a pipeline, Rapid Novor’s proteomics services enable internal drug development, and reagent and/or kit manufacturing with the utmost quality and reliability.

de novo mAb Sequencing

Obtain the sequence of an important antibody even after the hybridoma has died or mutated. Start with only a small protein sample.
Explore REmAb

Recombinant Expression

A good antibody is irreplaceable. By securing the protein sequence, scientists can safeguard a mAb down to the amino acid level and its PTMs for indefinite recombinant expression and for IP purposes.
Explore REmAb + Expression

Quality Control and Troubleshooting

Routinely confirm that the sequence of manufactured immunoreagents match the expected sequence. Save time troubleshooting cell line stability issues throughout your pipeline.
Explore MATCHmAb

Application Publications.

Ushering the New Era in Anti-Drug Antibody Assays with Next Generation Protein Sequencing

Tags: , , , , , , , , , , |

Anti-drug antibody (ADA) assays are critical to assess the clinical efficacy and safety of a biological drug and rely on control reagents that mimic the ADA response to the biological drug being tested. These positive controls typically consist of animal-derived pooled polyclonal antibodies or human monoclonal antibody reference panels against the target protein drug.

Ushering in the Future of Immunotherapy with Protein Sequencing

Tags: , , , , , , , , , , , , , |

Dating back to ancient Egypt, immunotherapy has a rich history of harnessing the power of the immune response to treat diseases. Today, immunotherapy is routinely used to fight cancer and treat viral diseases.

“The sequences have allowed us to have an “insurance policy” of sorts for critical proteins used in our various products.”

Talk to Our Scientists.

We Have Sequenced 3000+ Antibodies and We Are Eager to Help You.

Through next generation protein sequencing, Rapid Novor enables reliable discovery and development of novel reagents, diagnostics, and therapeutics. Thanks to our Next Generation Protein Sequencing and antibody discovery services, researchers have furthered thousands of projects, patented antibody therapeutics, and developed the first recombinant polyclonal antibody diagnostics.

Talk to Our Scientists.

We Have Sequenced 3000+ Antibodies and We Are Eager to Help You.

Through next generation protein sequencing, Rapid Novor enables timely and reliable discovery and development of novel reagents, diagnostics, and therapeutics. Thanks to our Next Generation Protein Sequencing and antibody discovery services, researchers have furthered thousands of projects, patented antibody therapeutics, and ran the first recombinant polyclonal antibody diagnostics

Talk to our scientists. We have sequenced over 3000 antibodies and we are eager to help you.